Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Epistemonikos ID: 6332260460752bae542b90fe6357c4320e58ba76
First added on: May 15, 2024